Labcorp Holdings Inc. (NYSE: LH) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
320.71
-2.02-0.63%
TA
Loading chart...
Snapshot
| Index | S&P 500 | P/E | 26.35 | EPS (ttm) | 12.17 | Insider Own | 0.52% | Shs Outstand | 82.00M | Perf Week | 2.94% |
| Market Cap | 26.30B | Forward P/E | 16.11 | EPS next Y | 19.90 | Insider Trans | -4.60% | Shs Float | 81.67M | Perf Month | -2.94% |
| Enterprise Value | 32.92B | PEG | 0.79 | EPS next Q | 4.65 | Inst Own | - | Short Float | 2.58% | Perf Quarter | 25.37% |
| Income | 1.01B | P/S | 1.83 | EPS this Y | 51.78% | Inst Trans | - | Short Ratio | 3.12 | Perf Half Y | 21.44% |
| Sales | 14.35B | P/B | 3.04 | EPS next Y | 8.46% | ROA | 5.41% | Short Interest | 2.10M | Perf YTD | 27.83% |
| Book/sh | - | P/C | 15.99 | EPS next 5Y | 8.69% | ROE | 11.57% | 52W High | 341.80 -6.17% | Perf Year | 16.17% |
| Cash/sh | - | P/FCF | 22.77 | EPS past 3/5Y | -9.17% -8.01% | ROIC | 7.93% | 52W Low | 244.52 31.16% | Perf 3Y | 56.82% |
| Dividend Est. | 2.88 (0.90%) | EV/EBITDA | 15.30 | Sales past 3/5Y | 5.55% -0.04% | Gross Margin | 27.85% | Volatility | 2.54% 2.34% | Perf 5Y | 24.05% |
| Dividend TTM | 2.88 (0.90%) | EV/Sales | 2.29 | EPS Y/Y TTM | 36.76% | Oper. Margin | 11.27% | ATR (14) | 7.84 | Perf 10Y | 168.35% |
| Dividend Ex-Date | Aug 28, 2026 | Quick Ratio | 1.53 | Sales Y/Y TTM | 10.30% | Profit Margin | 6.99% | RSI (14) | 49.59 | Recom | 2.26 |
| Dividend Gr. 3/5Y | 15.78% - | Current Ratio | 1.80 | EPS Q/Q | 14.71% | SMA20 | -1.96% | Beta | 0.85 | Target Price | 337.29 |
| Payout | 23.86% | Debt/Eq | 0.79 | Sales Q/Q | 5.78% | SMA50 | 2.31% | Rel Volume | 2.40 | Prev Close | 322.73 |
| Employees | 71,000 | LT Debt/Eq | 0.75 | Earnings | Oct 27 | SMA200 | 15.37% | Avg Volume | 713.64K | Price | 320.71 |
| IPO Date | Mar 29, 1990 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 4.41% 0.59% | Net Debt/EBITDA | 3.08 | Volume | 1,716,290 | Change | -0.63% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-11-26 | Reiterated | UBS | Buy | $320 → $380 |
| Sep-11-26 | Reiterated | Barclays | Equal Weight | $320 → $330 |
| Aug-10-26 | Reiterated | Mizuho Securities | Outperform | $320 → $355 |
| Jul-31-26 | Reiterated | Deutsche Bank | Hold | $276 → $306 |
| Jul-31-26 | Reiterated | Robert W. Baird | $338 → $352 | |
| Jul-31-26 | Reiterated | Morgan Stanley | Overweight | $303 → $338 |
| May-01-26 | Reiterated | Robert W. Baird | $332 → $334 | |
| Apr-08-26 | Reiterated | Evercore ISI Group | Outperform | $305 → $300 |
| Feb-24-26 | Reiterated | Piper Sandler | Neutral | $300 |
| Feb-18-26 | Reiterated | Robert W. Baird | $313 → $326 |
Latest News· Times ET
Sep-16-26
Sep-15-26
Sep-15-2610:31AM
Sep-11-26
Sep-10-26
03:00AM
Sep-09-26
Sep-09-2611:45PM
05:00AM
Great Point Partners III Sells MLM Medical Labs to Labcorpbusinesswire.com
04:55AM
Sep-08-26
Sep-08-2609:05AM
Sep-07-26
Sep-02-26
Aug-31-26
03:00AM
Aug-28-26
Aug-28-2604:30AM
Aug-26-26
Company
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 14,349 | 13,952 | 13,009 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 10,351 | 10,219 | 9,385 | — | — | — | — | — | — | |
| Gross Profit | 3,996 | 3,733 | 3,624 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 2,219 | 2,216 | 2,230 | — | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | — | — | — | |
| Other Operating Expense | 160 | 0 | 308 | — | — | — | — | — | — | |
| Operating Income | 1,618 | 1,516 | 1,087 | — | — | — | — | — | — | |
| Interest Expense | 227 | 224 | 208 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -156 | -185 | 81 | — | — | — | — | — | — | |
| Net Income Before Taxes | 1,234 | 1,108 | 960 | — | — | — | — | — | — | |
| Income Taxes | 231 | 230 | 212 | — | — | — | — | — | — | |
| Consolidated Net Income | 1,003 | 877 | 746 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 1,004 | 878 | 747 | — | — | — | — | — | — | |
| Net Income | 1,003 | 877 | 746 | — | — | — | — | — | — | |
| EPS (Recurring) | 12.17 | 10.54 | 8.89 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 12.17 | 10.54 | 8.89 | — | — | — | — | — | — | |
| EPS (Diluted) | 12.09 | 10.46 | 8.84 | — | — | — | — | — | — | |
| EBITDA | 2,152 | 2,013 | 1,811 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 26.53 | 23.98 | 25.94 | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.83 | 1.49 | 1.48 | — | — | — | — | — | — | |
| Gross Margin | 27.85 | 26.76 | 27.86 | — | — | — | — | — | — | |
| Operating Margin | 11.28 | 10.87 | 8.36 | — | — | — | — | — | — | |
| Net Margin | 6.99 | 6.29 | 5.73 | — | — | — | — | — | — | |
| Shares Outstanding | 82 | 83 | 84 | — | — | — | — | — | — | |
| Market Capitalization | 26,298 | 20,823 | 19,263 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| ANDERSON KERRII B | Director | Aug 17 '26 | Sale | 318.02 | 3,000 | 954,060 | 6,563 | Aug 18 |
| Schechter Adam H | President & CEO | Aug 11 '26 | Sale | 320.37 | 4,669 | 1,495,808 | 102,565 | Aug 12 |
| Summy Amy B. | EVP, Chief Marketing Officer | Aug 04 '26 | Sale | 306.74 | 924 | 283,428 | 6,956 | Aug 06 |
| Wilkinson Peter J | SVP, Chief Accounting Officer | Aug 03 '26 | Option Exercise | 209.25 | 1,338 | 279,977 | 3,108 | Aug 05 |
| Wilkinson Peter J | SVP, Chief Accounting Officer | Aug 03 '26 | Sale | 309.23 | 1,420 | 439,107 | 1,770 | Aug 05 |
| Vaughn Bryan T | EVP and President, Diagnostics | Jul 02 '26 | Sale | 286.19 | 234 | 66,968 | 6,746 | Jul 06 |
| Kyle Kathryn W | EVP, Chief Legal Officer | Jul 02 '26 | Sale | 286.19 | 92 | 26,329 | 3,904 | Jul 06 |
| Vaughn Bryan T | EVP and President, Diagnostics | Jul 01 '26 | Option Exercise | 0.00 | 327 | 0 | 7,073 | Jul 06 |
| Kyle Kathryn W | EVP, Chief Legal Officer | Jul 01 '26 | Option Exercise | 0.00 | 256 | 0 | 4,069 | Jul 06 |
| Kyle Kathryn W | EVP, Chief Legal Officer | Jun 08 '26 | Sale | 263.89 | 762 | 201,084 | 3,813 | Jun 10 |
| Schechter Adam H | President & CEO | May 11 '26 | Sale | 254.50 | 5,903 | 1,502,314 | 107,234 | May 13 |
| Wilkinson Peter J | SVP, Chief Accounting Officer | Mar 27 '26 | Sale | 267.05 | 1,633 | 436,093 | 1,852 | Mar 30 |
| Meltzer Jonathan C | EVP, Operations | Mar 27 '26 | Sale | 267.05 | 839 | 224,055 | 3,620 | Mar 30 |
| Schechter Adam H | President & CEO | Mar 03 '26 | Sale | 279.96 | 8,705 | 2,437,047 | 80,773 | Mar 05 |
| van der Vaart Sandra D | EVP, Corporate Affairs | Feb 27 '26 | Sale | 284.91 | 548 | 156,000 | 2,579 | Mar 03 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.